MYC and colorectal carcinoma: Since CRC needs more energy than normal cells to support their growth, inhibition of the c-Myc-mediated energy production will have a greater detrimental consequence in CRC than in normal tissues, which favors the development of dihydroartemisinin as an anti-CRC therapeutic agent.